BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-0.01%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.89B
AUM Growth
+$6.89B
(-8.5%)
Cap. Flow
-$366M
Cap. Flow
% of AUM
-5.31%
Top 10 Holdings %
Top 10 Hldgs %
36.47%
Holding
178
New
7
Increased
49
Reduced
68
Closed
19
Top Buys
| 1 |
Medtronic
MDT
|
$49.2M |
| 2 |
Align Technology
ALGN
|
$30.7M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$15.6M |
| 4 |
Veeva Systems
VEEV
|
$14.1M |
| 5 |
Legend Biotech
LEGN
|
$7.35M |
Top Sells
| 1 |
MYOV
Myovant Sciences Ltd.
MYOV
|
$159M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$27.3M |
| 3 |
DexCom
DXCM
|
$27.1M |
| 4 |
Cigna
CI
|
$26.9M |
| 5 |
Elevance Health
ELV
|
$26M |
Sector Composition
| 1 | Healthcare | 99.07% |
| 2 | Industrials | 0.84% |
| 3 | Energy | 0.03% |
| 4 | Communication Services | 0.01% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Jazz Pharmaceuticals
JAZZ
$7.99B
| $83.4M | 1.21% |
569,857
-186,779
| -25% | -$27.3M |
|
27
Exact Sciences
EXAS
$9.33B
| $83.1M | 1.21% |
1,225,042
-86,973
| -7% | -$5.9M |
|
28
Pacific Biosciences
PACB
$378M
| $81.4M | 1.18% |
7,026,106
+547,181
| +8% | +$6.34M |
|
29
HCA Healthcare
HCA
$95.4B
| $80.1M | 1.16% |
303,786
-27,520
| -8% | -$7.26M |
|
30
Option Care Health
OPCH
$4.7B
| $77.6M | 1.13% |
2,442,185
+11,763
| +0.5% | +$374K |
|
31
Apellis Pharmaceuticals
APLS
$3.51B
| $73.2M | 1.06% |
1,109,382
+5,165
| +0.5% | +$341K |
|
32
Tandem Diabetes Care
TNDM
$834M
| $72.8M | 1.06% |
1,793,763
+2,313
| +0.1% | +$93.9K |
|
33
Evolent Health
EVH
$1.11B
| $71.1M | 1.03% |
2,191,147
+207,494
| +10% | +$6.73M |
|
34
MacroGenics
MGNX
$121M
| $68.9M | 1% |
9,609,913
+630,000
| +7% | +$4.52M |
|
35
Relay Therapeutics
RLAY
$709M
| $68.7M | 1% |
4,172,600
-32,220
| -0.8% | -$531K |
|
36
Penumbra
PEN
$10.5B
| $66.4M | 0.96% |
238,172
+12,355
| +5% | +$3.44M |
|
37
Celldex Therapeutics
CLDX
$1.57B
| $64.8M | 0.94% |
1,800,000
| – | – |
|
38
Charles River Laboratories
CRL
$7.99B
| $61M | 0.89% |
302,446
+12,469
| +4% | +$2.52M |
|
|
SWAV
39
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $61M | 0.89% |
281,376
+33,760
| +14% | +$7.32M |
|
|
ACCD
40
DELISTED
Accolade, Inc. Common Stock
ACCD
| $58.1M | 0.84% |
4,041,801
+364,524
| +10% | +$5.24M |
|
41
Arvinas
ARVN
$580M
| $58.1M | 0.84% |
2,127,000
-23,412
| -1% | -$640K |
|
|
42
Align Technology
ALGN
$9.59B
| $57.2M | 0.83% |
171,140
+91,946
| +116% | +$30.7M |
|
43
Insmed
INSM
$30.3B
| $56.1M | 0.81% |
3,293,102
+15,895
| +0.5% | +$271K |
|
44
Idexx Laboratories
IDXX
$50.7B
| $55.5M | 0.81% |
110,928
+2,106
| +2% | +$1.05M |
|
45
Bio-Rad Laboratories Class A
BIO
$7.8B
| $54.5M | 0.79% |
113,739
+2,581
| +2% | +$1.24M |
|
46
Outset Medical
OM
$245M
| $53.5M | 0.78% |
2,906,759
+63,080
| +2% | +$1.16M |
|
47
Exelixis
EXEL
$9.95B
| $50.6M | 0.73% |
2,609,000
-64,500
| -2% | -$1.25M |
|
48
Thermo Fisher Scientific
TMO
$183B
| $49.8M | 0.72% |
86,333
+3,004
| +4% | +$1.73M |
|
|
49
Veeva Systems
VEEV
$44.4B
| $48.3M | 0.7% |
262,985
+76,728
| +41% | +$14.1M |
|
50
Transmedics
TMDX
$3.65B
| $47.7M | 0.69% |
629,484
-52,574
| -8% | -$3.98M |
|